You’ve probably never heard of Executive Order #13972. Signed by President Trump just days before leaving office, it greenlit what could be the most revolutionary technology of the decade… yet it has nothing to do with AI, blockchain, or mRNA vaccines.

Alexander Nolte Biography and Net Worth

CAO of Syndax Pharmaceuticals

Alexander Nolte has served as the Company’s Vice President, Chief Accounting Officer since September 2021 and previously served as Vice President, Corporate Finance since February 2021 and as Corporate Controller since April 2017. Prior to that, he served as Corporate Controller from July 2015 to April 2017 at CoLucid Pharmaceuticals, responsible for the financial operations of the company. From September 2013 to July 2015, he served as Director of Revenue Recognition and International Accounting at Aegerion Pharmaceuticals. From March 2008 to September 2013, Mr. Nolte held several finance positions at Genzyme Corporation. He began his professional career at KPMG Accountants NV in the Netherlands and PricewaterhouseCoopers LLP in Boston, Massachusetts. Mr. Nolte received his B.S. in Accountancy, from The Hague University (the Netherlands) and is a licensed Certified Public Accountant in the State of Massachusetts.

How do I contact Alexander Nolte?: The corporate mailing address for Mr. Nolte and other Syndax Pharmaceuticals executives is 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451. Syndax Pharmaceuticals can also be reached via phone at (781) 419-1400 and via email at [email protected]. Learn More on Alexander Nolte's contact information.
Has Alexander Nolte been buying or selling shares of Syndax Pharmaceuticals?: Alexander Nolte has not been actively trading shares of Syndax Pharmaceuticals during the last quarter. Most recently, Alexander Nolte sold 968 shares of the business's stock in a transaction on Tuesday, February 1st. The shares were sold at an average price of $16.65, for a transaction totalling $16,117.20. Learn More on Alexander Nolte's trading history.
Who are Syndax Pharmaceuticals' active insiders?: Syndax Pharmaceuticals' insider roster includes Fabrice Egros (Director), Pierre Legault (Director), Michael Metzger (COO), Michael Meyers (SVP), Briggs Morrison (CEO), Alexander Nolte (CAO), Peter Ordentlich (Insider), and Dennis Podlesak (Director). Learn More on Syndax Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Syndax Pharmaceuticals?: In the last year, insiders at the sold shares 6 times. They sold a total of 294,997 shares worth more than $6,006,050.17. The most recent insider tranaction occured on August, 9th when Director Briggs Morrison sold 52,855 shares worth more than $965,660.85. Insiders at Syndax Pharmaceuticals own 4.1% of the company. Learn More about insider trades at Syndax Pharmaceuticals.
Information on this page was last updated on 8/9/2023.

Alexander Nolte Insider Trading History at Syndax Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/1/2022	Sell	968	$16.65	$16,117.20

Alexander Nolte Buying and Selling Activity at Syndax Pharmaceuticals

Syndax Pharmaceuticals Company Overview

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $21.97

$21.15

$23.04

50 Day Range

MA: $22.61

$20.49

$24.57

2 Week Range

Now: $21.97

$11.22

$25.34

Volume

1,612,062 shs

Average Volume

1,132,510 shs

Market Capitalization

$1.87 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.03

Trump’s last act as President

From Porter & Company | Ad

For the full story, click here.